GO:1900038 negative regulation of cellular response to hypoxia: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900038 describes any process that stops, prevents, or reduces the frequency, rate, or extent of the cellular response to hypoxia.
• The term is a biological_process child of negative regulation of response to hypoxia and regulation of cellular response to hypoxia, and it directly opposes GO:0071456 (cellular response to hypoxia).
• Key molecular players include HIF1A, VHL, EGLN1/PHD2, EPAS1/HIF2A, and ARNT, which together form the core oxygen-sensing machinery.
• Loss of the cellular response to hypoxia in diabetes is linked to impaired HIF-1 regulation, illustrating the physiological importance of this negative regulatory layer.
• Hypoxia and ferroptosis are mechanistically intertwined, and negative regulation of the hypoxic response can influence ferroptotic cell death in cancer and other diseases.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators such as VHL, EGLN1, and SMARCB1.
Description
The cellular response to hypoxia is a fundamental adaptive program that allows cells to survive and function when oxygen availability drops. This program is orchestrated largely by the hypoxia-inducible factor (HIF) family of transcription factors, which activate hundreds of target genes involved in angiogenesis, metabolism, and survival. However, unrestrained or inappropriate activation of the hypoxic response can be detrimental, contributing to tumor progression, metabolic disorders, and chronic inflammatory conditions. Therefore, cells have evolved negative regulatory mechanisms that stop, prevent, or reduce the frequency, rate, or extent of the cellular response to hypoxia. The Gene Ontology term GO:1900038, negative regulation of cellular response to hypoxia, captures this essential counterbalancing process. Understanding GO:1900038 is critical for researchers because it defines the molecular brakes that keep the hypoxic response in check. Dysregulation of these brakes is implicated in a wide range of pathologies, including diabetes, osteoarthritis, sickle cell trait, and cancer. For example, in diabetes, the loss of the cellular response to hypoxia has been linked to impaired regulation of HIF-1, suggesting that negative regulatory components may be dysfunctional. In sickle cell trait, SMARCB1 has been shown to regulate the hypoxic stress response, highlighting how chromatin remodeling factors can act as negative regulators. This article provides a research-grade synthesis of GO:1900038, integrating the official QuickGO definition with real PubMed literature. We cover the core molecular mechanisms, key genes, disease associations, and state-of-the-art experimental methods, including CRISPR-based models, to support both basic and translational research.
negative regulation of cellular response to hypoxia At A Glance
| GO ID | GO:1900038 |
|---|---|
| GO term | negative regulation of cellular response to hypoxia |
| Ontology | biological_process |
| Synonym | down regulation of cellular response to hypoxia; inhibition of cellular response to hypoxia; negative regulation of cellular response to hypoxic stress; negative regulation of cellular response to lowered oxygen tension |
| Major function | Stops, prevents, or reduces the cellular response to hypoxia, often by targeting HIF1A stability or activity |
| Parent terms | negative regulation of response to hypoxia; regulation of cellular response to hypoxia |
| Related terms | cellular response to hypoxia (GO:0071456); regulation of cellular response to hypoxia (GO:1900037) |
| Disease relevance | Diabetes, osteoarthritis, sickle cell trait, cancer, and ferroptosis-related pathologies |
| Key regulators | HIF1A, VHL, EGLN1, EPAS1, ARNT, SMARCB1 |
What Is GO:1900038?
GO:1900038, negative regulation of cellular response to hypoxia, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the cellular response to hypoxia. In other words, it encompasses all molecular events that dampen or shut down the cellular reaction to low oxygen levels. This term is a negative regulatory counterpart to the cellular response to hypoxia (GO:0071456) and is a child of negative regulation of response to hypoxia and regulation of cellular response to hypoxia. It includes mechanisms such as oxygen-dependent degradation of HIF1A, inhibition of HIF transcriptional activity, and modulation of downstream signaling pathways that would otherwise promote adaptation to hypoxia.
Why Is negative regulation of cellular response to hypoxia Important in Cell Biology?
GO:1900038 is important because it defines the molecular mechanisms that prevent excessive or inappropriate activation of the hypoxic response. Without negative regulation, cells could undergo uncontrolled angiogenesis, metabolic reprogramming, and survival signaling, which are hallmarks of cancer and other diseases. Moreover, the loss of negative regulation can lead to chronic inflammation, fibrosis, and impaired tissue function, as seen in diabetes and osteoarthritis. Understanding this term helps researchers identify therapeutic targets to either enhance or inhibit the hypoxic response in a context-dependent manner.
• Provides a framework for understanding how cells avoid runaway HIF activation under normoxia or mild hypoxia.
• Dysregulation of negative regulators like VHL and EGLN1 is directly linked to cancer predisposition and tumor progression.
• Loss of the cellular response to hypoxia in diabetes highlights the clinical relevance of negative regulatory mechanisms.
• SMARCB1-dependent regulation of the hypoxic stress response in sickle cell trait demonstrates the role of chromatin remodelers in GO:1900038.
• Hypoxia and ferroptosis crosstalk suggests that negative regulation of the hypoxic response can modulate cell death pathways.
• Iron metabolism and ILC2 function are influenced by hypoxia-related pathways, expanding the physiological scope of this term.
• Plexin-B3 and MET signaling in breast cancer stem cells intersect with hypoxic adaptation, indicating broader signaling integration.
• Osteoarthritis involves HIF-mediated pathways, and negative regulation may protect against cartilage degradation.
• Hypoxia-responsive CAR-T cells show reduced exhaustion, underscoring the therapeutic potential of manipulating this process.
• Viral infections such as foot-and-mouth disease virus manipulate autophagy and IRF3, which may intersect with hypoxic signaling.
What Happens During negative regulation of cellular response to hypoxia?
Oxygen-dependent degradation of HIF1A
In simple terms: When oxygen is available, a molecular tag marks HIF1A for destruction, preventing it from turning on hypoxia genes.
Under normoxic conditions, prolyl hydroxylases (EGLN1/PHD2, EGLN2/PHD1, EGLN3/PHD3) hydroxylate specific proline residues on HIF1A. This modification is recognized by the von Hippel-Lindau tumor suppressor (VHL), which recruits an E3 ubiquitin ligase complex, leading to polyubiquitination and proteasomal degradation of HIF1A. This process is a primary mechanism of negative regulation of the cellular response to hypoxia, as it keeps HIF1A levels low when oxygen is plentiful. In diabetes, impaired regulation of HIF-1 and the loss of the cellular response to hypoxia have been observed, suggesting that this degradation pathway may be disrupted.
Inhibition of HIF transcriptional activity
In simple terms: Even if HIF proteins are present, other factors can block them from activating genes.
Beyond degradation, negative regulation can occur at the level of transcriptional activity. For instance, competitive inhibitors such as the aryl hydrocarbon receptor nuclear translocator (ARNT) splice variants or inhibitory PAS domain proteins can sequester HIF1A or prevent its binding to hypoxia response elements (HREs). Additionally, post-translational modifications like acetylation or SUMOylation can reduce HIF transactivation capacity. These mechanisms ensure that the hypoxic response is finely tuned and can be rapidly shut down when oxygen levels are restored.
Chromatin remodeling and epigenetic silencing
In simple terms: The cell can pack away the DNA regions that control hypoxia genes, making them harder to turn on.
Epigenetic mechanisms contribute to the negative regulation of the cellular response to hypoxia. SMARCB1, a core subunit of the SWI/SNF chromatin remodeling complex, has been shown to regulate the hypoxic stress response in sickle cell trait. Loss of SMARCB1 leads to altered chromatin accessibility at hypoxia-inducible genes, thereby modulating the response. This indicates that ATP-dependent chromatin remodeling can act as a brake on hypoxia signaling, adding a layer of transcriptional control.
MicroRNA and non-coding RNA-mediated repression
In simple terms: Small RNA molecules can bind to HIF messages and stop them from making protein.
Several microRNAs (miRNAs) are induced under hypoxia and target HIF1A or its downstream effectors, forming a negative feedback loop. For example, miR-155, miR-17-92, and miR-20b can downregulate HIF1A translation or stability. These non-coding RNAs provide a rapid and reversible mechanism to dampen the hypoxic response. Their dysregulation has been implicated in cancer and inflammatory diseases, where they contribute to pathological angiogenesis and metabolic reprogramming.
Metabolic and redox feedback
In simple terms: Changes in cell metabolism can signal back to reduce the hypoxia response.
Hypoxia-induced metabolic shifts, such as increased glycolysis and altered iron metabolism, can generate feedback that limits the hypoxic response. Iron availability controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function, and iron-dependent enzymes like prolyl hydroxylases require iron as a cofactor. Thus, fluctuations in iron or reactive oxygen species (ROS) can modulate PHD activity and HIF stability, contributing to negative regulation.
Key Genes Involved in GO:1900038 negative regulation of cellular response to hypoxia
The following genes and proteins are central to the negative regulation of the cellular response to hypoxia, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIF1A | Master transcription factor of the hypoxic response; its degradation is a key negative regulatory node | Target for KO and point-mutation studies to dissect oxygen sensing |
| VHL | E3 ubiquitin ligase substrate receptor that targets hydroxylated HIF1A for degradation | Frequently mutated in von Hippel-Lindau disease and clear cell renal cell carcinoma |
| EGLN1 | Prolyl hydroxylase that marks HIF1A for VHL-mediated degradation | Oxygen sensor; KO models show constitutive HIF activation |
| EGLN2 | Prolyl hydroxylase isoform with overlapping function in HIF regulation | Potential compensatory role in EGLN1 knockout models |
| EGLN3 | Prolyl hydroxylase isoform; negative regulator of HIF | Hypoxia-inducible itself, forming a feedback loop |
| EPAS1 | HIF2A; transcription factor with distinct targets from HIF1A | Implicated in cancer and pulmonary hypertension |
| ARNT | HIF beta subunit; required for HIF transcriptional activity | Modulates HIF dimerization and activity |
| SMARCB1 | Chromatin remodeler that regulates hypoxic stress response | Loss linked to sickle cell trait and malignant rhabdoid tumors |
| IRF3 | Transcription factor involved in antiviral response; degraded by FMDV VP1 via autophagy | Intersection of hypoxia and viral replication |
| YTHDF2 | m6A reader that can affect mRNA stability, including HIF1A transcripts | Targeted for degradation by FMDV VP1 |
| PLXNB3 | Plexin-B3, involved in MET signaling and breast cancer stem cell specification | May intersect with hypoxic niche signaling |
| MET | Receptor tyrosine kinase; downstream of Plexin-B3 | Promotes metastasis and stemness under hypoxia |
| ILC2 | Group 2 innate lymphoid cells; iron metabolism affects their function | Hypoxia-iron crosstalk in airway hyperreactivity |
| CAR-T | Chimeric antigen receptor T cells; hypoxia-responsive CAR-T show reduced exhaustion | Therapeutic manipulation of hypoxic response |
| Ferroptosis regulators | GPX4, ACSL4, etc.; hypoxia and ferroptosis are mechanistically linked | Negative regulation of hypoxia may influence ferroptotic sensitivity |
| Osteoarthritis-related HIFs | HIF1A and HIF2A in cartilage homeostasis | Targets for osteoarthritis therapy |
| Diabetes-related HIF regulators | HIF-1 regulation and loss of hypoxic response in diabetes | Model for metabolic dysfunction |
| Viral autophagy factors | Autophagy machinery degrading YTHDF2 and IRF3 | Host-pathogen interplay with hypoxia |
How Is negative regulation of cellular response to hypoxia Regulated?
The negative regulation of the cellular response to hypoxia is itself tightly regulated at multiple levels. Oxygen availability directly controls the activity of prolyl hydroxylases (EGLN1-3), which require molecular oxygen, iron, and 2-oxoglutarate as cofactors. Metabolic signals such as iron levels and ROS can modulate PHD activity, thereby influencing HIF stability. Additionally, feedback loops involving microRNAs and hypoxia-inducible proteins like EGLN3 ensure that the response is self-limiting. Chromatin remodeling complexes, such as SWI/SNF containing SMARCB1, can alter the accessibility of hypoxia-responsive genes, providing an epigenetic layer of regulation. Finally, viral infections can hijack autophagy to degrade factors like YTHDF2 and IRF3, potentially impacting the hypoxic response.
negative regulation of cellular response to hypoxia and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VHL | Von Hippel-Lindau disease; clear cell renal cell carcinoma | VHL knockout or point-mutation in renal cell lines |
| HIF1A | Solid tumors; diabetes complications | HIF1A knockout and hypoxia-responsive overexpression |
| SMARCB1 | Sickle cell trait; malignant rhabdoid tumors | SMARCB1 knockout in hematopoietic cells |
| EGLN1 | Cancer; metabolic disorders | EGLN1 knockout and catalytic-dead point mutant |
| PLXNB3 | Breast cancer metastasis | PLXNB3 overexpression and knockout in breast cancer models |
Cancer and the hypoxic tumor microenvironment
In solid tumors, hypoxia drives aggressive phenotypes, including angiogenesis, metastasis, and therapy resistance. Negative regulation of the cellular response to hypoxia is often subverted in cancer; for example, VHL mutations lead to constitutive HIF1A stabilization, promoting tumor growth. Conversely, enhancing negative regulation could be therapeutic. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors, suggesting that engineering the hypoxic response can improve immunotherapy. Ferroptosis, an iron-dependent cell death, is closely linked to hypoxia, and modulating negative regulators may sensitize tumors to ferroptosis inducers.
Diabetes and metabolic disorders
In diabetes, the loss of the cellular response to hypoxia is associated with impaired HIF-1 regulation, which contributes to poor wound healing, neuropathy, and cardiovascular complications. Negative regulatory mechanisms that normally keep HIF in check may become dysregulated, leading to inadequate adaptive responses. Understanding GO:1900038 could reveal targets to restore proper hypoxic signaling in diabetic tissues.
Osteoarthritis and cartilage degeneration
Osteoarthritis involves chronic low-grade inflammation and cartilage degradation, in which HIFs play a dual role. HIF1A can protect cartilage under hypoxia, while HIF2A may promote catabolic processes. Negative regulation of the hypoxic response helps maintain homeostasis, and its dysregulation may tip the balance toward degeneration. Targeting these pathways could offer disease-modifying therapies.
Sickle cell trait and hematological stress
SMARCB1 regulates the hypoxic stress response in sickle cell trait, linking chromatin remodeling to red blood cell pathology. This suggests that negative regulation of hypoxia signaling is critical for managing oxidative stress in hemoglobinopathies. Experimental models using SMARCB1 knockout or knock-in could elucidate its protective role.
From negative regulation of cellular response to hypoxia-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does VHL loss stabilize HIF1A under normoxia? | VHL knockout cell line |
| What is the effect of a catalytically inactive EGLN1 mutant? | EGLN1 point mutation (e.g., catalytic dead) knock-in |
| How does SMARCB1 regulate hypoxia genes? | SMARCB1 knockout and tagged knock-in for ChIP-seq |
| Can overexpression of a negative regulator suppress tumor growth? | Doxycycline-inducible overexpression of VHL or EGLN1 |
| What is the role of HIF2A in osteoarthritis? | EPAS1 knockout and overexpression in chondrocytes |
| Does hypoxia-responsive CAR-T improve efficacy? | Knock-in of hypoxia-responsive elements into CAR-T cells |
How to Study the negative regulation of cellular response to hypoxia Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify HIF target genes affected by negative regulators |
| Western blot | Protein levels and modifications | Assess HIF1A stability and PHD activity |
| ChIP-seq | Genome-wide binding of transcription factors | Map HIF and SMARCB1 binding sites |
| Proteomics | Protein abundance and interactions | Discover novel components of the negative regulatory complex |
| Cycloheximide chase | Protein half-life | Measure HIF1A degradation rate |
| Luciferase reporter assay | Transcriptional activity of HREs | Quantify HIF-driven transcription |
| Ferroptosis assays | Lipid peroxidation and cell death | Link hypoxia regulation to ferroptosis |
| CRISPR screening | Gene essentiality and pathway discovery | Identify novel negative regulators of hypoxia response |
Transcriptomic profiling of hypoxia response
RNA-seq and microarray analysis can quantify global changes in gene expression when negative regulators are perturbed. For example, comparing VHL knockout versus wild-type cells under normoxia and hypoxia reveals HIF target genes that are constitutively activated. This approach helps define the footprint of GO:1900038.
Proteomic analysis of HIF stability
Western blotting and mass spectrometry-based proteomics can measure HIF1A protein levels and post-translational modifications. Cycloheximide chase assays determine HIF1A half-life, while ubiquitination assays detect VHL-mediated polyubiquitination.
Chromatin immunoprecipitation and sequencing (ChIP-seq)
ChIP-seq for HIF1A, HIF2A, or SMARCB1 identifies genome-wide binding sites at hypoxia-responsive genes. This method reveals how chromatin remodelers and transcription factors cooperate to negatively regulate the hypoxic response.
Functional assays for hypoxic adaptation
Cell proliferation, migration, and angiogenesis tube formation assays under hypoxia assess the functional consequences of manipulating negative regulators. Ferroptosis sensitivity can be measured using lipid peroxidation and cell viability assays.
How CRISPR Can Be Used to Study GO:1900038 negative regulation of cellular response to hypoxia
Knockout
CRISPR knockout of negative regulators such as VHL, EGLN1, or SMARCB1 leads to constitutive activation of the hypoxic response, providing a powerful model to study GO:1900038. For example, VHL knockout cells stabilize HIF1A under normoxia, mimicking a loss of negative regulation. These models are essential for identifying downstream targets and testing therapeutic interventions.
Point Mutation
Point mutations can dissect specific domains or catalytic residues. For instance, a catalytically dead EGLN1 mutant (e.g., H358A) prevents HIF hydroxylation without affecting protein interactions, allowing separation of enzymatic versus scaffolding functions. Similarly, point mutations in VHL that disrupt substrate recognition can model disease-associated variants.
Knock-in
Knock-in of tagged versions (e.g., HA, FLAG, or GFP) of negative regulators enables endogenous protein tracking and interaction studies. Tagged SMARCB1 knock-in allows ChIP-seq and immunoprecipitation to map its role in chromatin remodeling at hypoxia genes. Knock-in of hypoxia-responsive elements into CAR-T cells is another application.
Overexpression
Overexpression of negative regulators such as VHL or EGLN1 can suppress the hypoxic response and inhibit tumor growth. Doxycycline-inducible systems allow controlled expression to study dosage effects. Overexpression of Plexin-B3 in breast cancer cells has been used to investigate MET signaling and stem cell specification under hypoxic conditions.
How EDITGENE Supports negative regulation of cellular response to hypoxia Research
Researchers studying negative regulation of cellular response to hypoxia-related genes often need to determine whether a candidate gene is causally involved in dampening the hypoxic response or is merely a bystander. This requires precise genetic manipulation, which is best achieved through CRISPR-based models. EDITGENE provides a comprehensive suite of services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous interrogation of GO:1900038.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cellular response to hypoxia research.
Frequently Asked Questions About negative regulation of cellular response to hypoxia
What is GO:1900038?
GO:1900038 is the Gene Ontology term for negative regulation of cellular response to hypoxia, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the cellular response to hypoxia.
What genes are involved in negative regulation of cellular response to hypoxia?
Key genes include HIF1A, VHL, EGLN1, EGLN2, EGLN3, EPAS1, ARNT, and SMARCB1, among others.
How does VHL negatively regulate the hypoxic response?
VHL recognizes hydroxylated HIF1A and targets it for ubiquitination and proteasomal degradation, thereby preventing HIF-driven transcription under normoxia.
What is the role of prolyl hydroxylases in this process?
Prolyl hydroxylases (EGLN1-3) hydroxylate HIF1A in an oxygen-dependent manner, creating a binding site for VHL and initiating HIF1A degradation.
How is negative regulation of hypoxia linked to cancer?
Loss of negative regulators such as VHL leads to constitutive HIF activation, promoting angiogenesis, metastasis, and therapy resistance in tumors.
Can CRISPR be used to study GO:1900038?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the causal roles of negative regulators in the hypoxic response.
What diseases are associated with dysregulated negative regulation of hypoxia?
Diabetes, osteoarthritis, sickle cell trait, and various cancers have been linked to altered negative regulation of the hypoxic response.
How does hypoxia relate to ferroptosis?
Hypoxia and ferroptosis are mechanistically connected; negative regulation of the hypoxic response can influence iron-dependent lipid peroxidation and cell death.
What methods are used to study negative regulation of cellular response to hypoxia?
Common methods include RNA-seq, western blotting, ChIP-seq, proteomics, luciferase reporter assays, and CRISPR screens.
What services does EDITGENE offer for hypoxia research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services tailored to hypoxia research.
Conclusion
GO:1900038, negative regulation of cellular response to hypoxia, represents a critical layer of control that prevents excessive or inappropriate activation of the hypoxic response. Its dysregulation is implicated in cancer, diabetes, osteoarthritis, and hematological disorders, making it a rich area for therapeutic targeting. Advances in CRISPR-based models and multi-omics approaches are accelerating our understanding of the molecular players and mechanisms involved. EDITGENE stands ready to support researchers with custom cell models and screening services to unravel the complexities of this essential biological process.
References
- 1. Zhu X et al.. 2024. Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors.. Cancer Res 84(1):84-100 PMID: 37874330
- 2. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 3. Bento CF et al.. 2011. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes.. Diabetologia 54(8):1946-56 PMID: 21614571
- 4. Liu XQ et al.. 2024. Hypoxia and ferroptosis.. Cell Signal 122:111328 PMID: 39094672
- 5. Zhang XA et al.. 2023. Mechanism of HIFs in osteoarthritis.. Front Immunol 14:1168799 PMID: 37020556
- 6. Soeung M et al.. 2023. SMARCB1 regulates the hypoxic stress response in sickle cell trait.. Proc Natl Acad Sci U S A 120(21):e2209639120 PMID: 37186844
- 7. Hurrell BP et al.. 2024. Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function.. Sci Transl Med 16(746):eadk4728 PMID: 38718131
- 8. Zuo Q et al.. 2023. Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis.. Cell Rep 42(3):112164 PMID: 36857181
